Abstract
Fluoroquinolones (FQs) are used for the complex treatment of mono, poly, and multiresistant Tuberculosis (TB) and are the most efficient among resistant TB treatment drugs. Disease caused by fluoroquinolone-resistant (FQ-R) TB strains, are extremely hard to manage and treatment efficacy is quite low.
Aim of the study: Usage of nanotechnologies to study the ability of FQs, particularly moxifloxacin(Mfx), to restore antituberculosis efficacy.
Materials and Methods: Standard dose of Mfx and 20 nanometer silver nanoparticle suspension solution with 6 different concentrations: 0,25%; 0,5% ; 1%; 2,5%; 5%, 10% (each silver nanoparticle concentrated suspension solution that was in the composite was added to already grown 50 resistant cultures) was added to FQ-R M.tuberculosis strains. The suppressive effect of Mfx and different concentrations of silver nanocomposite suspension was evaluated according to the growth of M.tuberculosis using the BACTEC™ MGIT 960™ TB System.
Results: The addition of Mfx and silver nanoparticles on FQ-R M.tuberculosis strains completely suppressed the growth of M.tuberculosis in 54,3% of cases; Using 20-nanometer silver nanoparticle 2,5% suspension with a standard dose of Mfx, resulted in bactericidal effect in 90% of cases, and in 100% when 5% and 10% suspension were applied.
Conclusion: Usage of silver nanoparticles and Mfx composite on Mfx resistant M.tuberculosis strains confirmed the potential influence of silver nanoparticles on overcoming FQ resistance, prompting further research in this area.
Footnotes
Cite this article as Eur Respir J 2022; 60: Suppl. 66, 1592.
This article was presented at the 2022 ERS International Congress, in session “-”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2022
